EyePoint Pharmaceuticals (NASDAQ:EYPT) has commercially launched YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg in the U.S. for the treatment of chronic non-infectious...
EyePoint Pharmaceuticals (NASDAQ:EYPT) is up 8% premarket on light volume on the heels of its U.S. commercial launch of YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg...
EyePoint Pharmaceuticals (EYPT +2.1%) plans to launch two products this quarter, DEXYCU (dexamethasone intraocular suspension) 9% for the treatment of postoperative inflammation in...
Investors in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 18, 2019...
For Immediate ReleaseChicago, IL – June 4, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts...
As of late, it has definitely been a great time to be an investor in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) . The stock has moved higher by 40% in the past month, while it...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Buy||Buy||Sell||Sell||Strong Sell|
|Technical Indicators||Strong Sell||Strong Sell||Strong Buy||Strong Sell||Strong Sell|
|Summary||Neutral||Neutral||Neutral||Strong Sell||Strong Sell|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Abandoned Baby Bullish||15||Current|
|Belt Hold Bullish||15||Current|
|Morning Doji Star||15||Current|
|Belt Hold Bullish||30||Current|
|Bullish doji Star||1W||Current|
|Bullish doji Star||15||1||Nov 13, 2019 03:30PM|
|Bullish Engulfing||30||3||Nov 13, 2019 02:00PM|
|Doji Star Bearish||1W||5||Oct 06, 2019|
Eyepoint Pharmaceuticals, Inc., formerly pSivida Corp, develops drug delivery products primarily for the treatment of chronic eye diseases. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert. Medidur is designed to treat chronic non-infectious uveitis affecting the posterior segment of the eye (posterior segment uveitis). ILUVIEN is an injectable micro-insert that provides treatment of DME from a single injection. Retisert is an implant that provides treatment of posterior segment uveitis. Its product development program is focused on utilizing its two technology platforms, Durasert and Tethadur, to deliver drugs and biologics to treat chronic diseases.Read More
|Securities Investor Protection Corporation (United States)||$0||Start Trading|
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$500||Start Trading|
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.